InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
62,948.95
(
0.09%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 201369

Monday, 06/20/2016 8:14:31 AM

Monday, June 20, 2016 8:14:31 AM

Post# of 251706
ENTA begins EDP-494 dosing in GT1/GT3 HCV patients:

http://finance.yahoo.com/news/enanta-pharmaceuticals-initiates-proof-concept-110000870.html

This is the third stage of the phase-1 trial, in which HCV patients will be given two doses of EDP-494 monotherapy for 14 days (https://www.clinicaltrials.gov/ct2/show/NCT02652377 ); the first two stages of the trial were conducted in healthy volunteers and determined the doses to test in HCV patients.

EDP-494 is a cyclophilin inhibitor that is wholly owned by ENTA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up